Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.
Theoret
Marc R
MR
Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Arlen
Philip M
PM
Pazdur
Mary
M
Dahut
William L
WL
Schlom
Jeffrey
J
Gulley
James L
JL
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology*; D000943:Antigens, Differentiation / Q000276:immunology*; D001859:Bone Neoplasms / Q000556:secondary / Q000628:therapy*; D060908:CTLA-4 Antigen; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D005822:Genetic Vectors / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000276:immunology / Q000628:therapy*; D017430:Prostate-Specific Antigen / Q000235:genetics / Q000276:immunology* / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000276:immunology / Q000628:therapy*
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D000943:Antigens, Differentiation; D060908:CTLA-4 Antigen; C556706:CTLA4 protein, human; D019496:Cancer Vaccines; D017430:Prostate-Specific Antigen